Simvastatin Significantly Reduced Alcohol-Induced Cardiac Damage in Adolescent Mice
Makgotso Nchodu1, Alice Efuntayo1, Robin du Preez1
1School of Anatomical Sciences, Faculty of Health Sciences, University of the Witwatersrand, 7 York Road, Parktown, Johannesburg, 2193, Republic of South Africa.
Abstract:
Alcohol abuse by adolescents is becoming a serious health concern as they often progress to becoming alcoholics later in life which may lead to heart problems. Chronic alcohol use alters the cardiac function and structure, such as haemodynamic changes, weakening and loss of cardiomyocytes, myocardial fibrosis, and inflammation. Simvastatin is a commonly used drug for the treatment and management of various cardiovascular problems but information on its protective effects against alcohol-induced cardiomyocyte hypertrophy, fibrosis, and inflammation is lacking in the literature. Four-week-old male (n = 5) and female (n = 5) C57BL/6 J mice were assigned to each experimental group: (I) NT-no administration of alcohol or Simvastatin; (II) ALC-2.5 g/Kg/day of 20% alcohol via intraperitoneal injection (i.p.); (III) SIM-5 mg/Kg/day of Simvastatin via oral gavage; (iv) ALC + SIM5-5 mg/Kg/day of Simvastatin via oral gavage followed by 2.5 g/Kg/day of 20% alcohol via i.p.; and (v) ALC + SIM15-15 mg/Kg/day Simvastatin via oral gavage followed by 2.5 g/Kg/day of 20% alcohol via i.p. After the 28-day treatment period, the heart was removed and processed for H&E, Masson's trichrome, or TNF-α immunolabelling. The area and diameter of cardiomyocytes were measured on the H&E-stained sections. The distribution of collagen or TNF-α expression was quantified using the deconvolution tool of ImageJ software. The results confirmed alcohol-induced toxicity on the cardiomyocytes and Simvastatin reduced alcohol-induced cardiomyocyte hypertrophy, fibrosis, and inflammation in both sexes. This study demonstrated that Simvastatin, an FDA approved and easily accessible drug, may be beneficial in lowering the prevalence of alcohol-induced cardiovascular diseases (especially in adolescents) which will have a huge financial implication on health systems worldwide.
Insights
Adolescent alcohol abuse harms the heart, causing cardiomyocyte damage. Simvastatin treatment effectively reduced alcohol-induced heart problems like hypertrophy, fibrosis, and inflammation in mice.
Area of Science:
- Cardiovascular Science
- Pharmacology
- Toxicology
Background:
- Adolescent alcohol abuse is a growing health concern, often leading to chronic alcoholism and cardiovascular issues.
- Chronic alcohol consumption negatively impacts cardiac function and structure, causing cardiomyocyte damage, fibrosis, and inflammation.
- Existing research lacks data on Simvastatin's protective effects against alcohol-induced cardiac problems.
Purpose of the Study:
- To investigate the protective effects of Simvastatin against alcohol-induced cardiomyocyte hypertrophy, fibrosis, and inflammation in a mouse model.
- To evaluate Simvastatin's efficacy in mitigating cardiac damage caused by chronic alcohol exposure in both male and female mice.
Main Methods:
- Four-week-old male and female C57BL/6J mice were divided into groups receiving alcohol, Simvastatin, or a combination.
- Alcohol was administered via intraperitoneal injection, while Simvastatin was given via oral gavage for 28 days.
- Cardiac tissues were analyzed using H&E, Masson's trichrome staining, and TNF-α immunolabelling to assess cardiomyocyte size, collagen distribution, and inflammation.
Main Results:
- Alcohol administration led to significant toxicity in cardiomyocytes, including hypertrophy and increased fibrosis and inflammation.
- Simvastatin treatment, at both 5 mg/Kg and 15 mg/Kg doses, effectively reduced alcohol-induced cardiomyocyte hypertrophy.
- Simvastatin also mitigated alcohol-induced myocardial fibrosis and inflammation in both male and female mice.
Conclusions:
- Simvastatin demonstrates significant cardioprotective effects against alcohol-induced damage, including hypertrophy, fibrosis, and inflammation.
- This study suggests Simvastatin, an accessible and FDA-approved drug, may be beneficial in preventing alcohol-related cardiovascular diseases, particularly in adolescents.
- The findings have potential implications for reducing the global health system's financial burden associated with alcohol-induced heart conditions.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:27CNS Depressants: Alcohol and Nicotine